Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity

Creative Commons License

Kciuk M., Gielecińska A., Mujwar S., Kołat D., Kałuzińska-Kołat Ż., Celik İ., ...More

CELLS, vol.12, no.4, pp.1-30, 2023 (SCI-Expanded, Scopus)

  • Publication Type: Article / Article
  • Volume: 12 Issue: 4
  • Publication Date: 2023
  • Doi Number: 10.3390/cells12040659
  • Journal Name: CELLS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, EMBASE, MEDLINE, Directory of Open Access Journals
  • Page Numbers: pp.1-30
  • Keywords: adriamycin, apoptosis, DNA damage response (DDR), doxorubicin, immunotherapy
  • Open Archive Collection: AVESIS Open Access Collection
  • Erciyes University Affiliated: Yes

Abstract

Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in clinical use. However, the precise mechanisms of DOX’s action are not fully understood. Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage, reactive oxygen species (ROS) production, apoptosis, senescence, autophagy, ferroptosis, and pyroptosis induction, as well as its immunomodulatory role. This review aims to collect information on the anticancer mechanisms of DOX as well as its influence on anti-tumor immune response, providing a rationale behind the importance of DOX in modern cancer therapy.